# Reframe **Source:** https://geo.sig.ai/brands/reframe **Vertical:** Healthcare **Subcategory:** General **Tier:** Challenger **Website:** reframeapp.com **Last Updated:** 2026-04-14 ## Summary SF YC W21 alcohol reduction app at $13M ARR with 150K+ paying customers; $17.4M Series B Goodwater 2022 with neuroscience-based CBT and community support competing with Monument for gray-area drinker digital behavior change. ## Company Overview Reframe (formerly Glucobit) is a San Francisco-based digital health platform — backed by Y Combinator (W21) — providing people seeking to quit or reduce alcohol consumption with a neuroscience-based mobile app that combines behavioral psychology, habit tracking, and community support, achieving $13 million in annual revenue with 150,000+ paying customers after 10x growth in 12 months and 3,000% growth in 6 months to become one of the top health apps on the App Store. Founded in 2018 by Ziyi Gao and Vedant Pradeep, Reframe raised $17.4 million in a Series B in January 2022 from Goodwater Capital, applying evidence-based alcohol reduction techniques (including CBT, mindfulness, and neuroscience education about alcohol's brain effects) to the 30 million Americans who want to drink less but don't seek traditional addiction treatment. Reframe's alcohol reduction platform addresses the care gap between heavy drinking and formal addiction treatment: alcohol use disorder affects 29 million Americans, but only a fraction receive any treatment — most people who drink more than they want to exist in the "gray area" between social drinking and diagnosable addiction, and they don't seek AA, rehab, or clinical interventions because they don't identify as alcoholics. Reframe's non-stigmatizing, neuroscience-framed approach (explaining why alcohol creates cravings at a neurological level, providing daily science lessons about alcohol's health effects, and offering habit-building tools for identifying triggers and replacing drinking habits) meets gray-area drinkers where they are — providing structured support through the app without requiring clinical label or treatment program enrollment. In 2025, Reframe competes in the alcohol reduction apps, digital addiction support, and behavioral health market with Monument (online alcohol treatment, $22M raised), Ria Health (alcohol treatment app, $18M raised), and Tempest (sobriety platform, acquired by Monument) for consumer seeking alcohol moderation or sobriety digital health support platform adoption. Goodwater Capital's Series B investment reflects consumer digital health and behavior change app conviction. Y Combinator W21 backing connects Reframe with the digital therapeutics and mental health investor community. The 150,000+ paying subscribers at $13M ARR demonstrates the large addressable market in consumer alcohol reduction. The 2025 strategy focuses on employer benefit partnerships (alcohol misuse costs employers $250B annually in lost productivity), building the physician referral channel for clinical integration, and expanding the international market where alcohol reduction app adoption is growing in Europe and Australia. ## Frequently Asked Questions ### What is Reframe? Reframe (formerly Glucobit) is a digital health platform founded in 2018 that helps people quit or cut back on alcohol use through a neuroscience-based app. The platform combines behavioral psychology, habit tracking, and community support to help users reduce alcohol consumption and improve their health. ### What products and services does Reframe offer? Reframe offers an alcohol reduction app featuring habit tracking, behavioral psychology tools, neuroscience-based techniques, community support, and structured programs. These evidence-based tools are designed to help users reduce their alcohol consumption effectively. ### Who is Reframe for? Reframe is designed for individuals seeking to quit or cut back on alcohol use and improve their overall health. The platform serves over 100,000 users who want to reduce their alcohol consumption through structured, evidence-based programs. ### When was Reframe founded and by whom? Reframe was founded in 2018 by Ziyi Gao and Vedant Pradeep. The company participated in Y Combinator's Winter 2021 (W21) cohort. ### Where is Reframe based? Reframe is headquartered in Atlanta, Georgia. ### What funding has Reframe raised? Reframe raised $17.4 million in a Series B funding round in January 2022, led by Goodwater Capital. The company is part of Y Combinator's Winter 2021 cohort. ### What are Reframe's key achievements and metrics? Reframe has achieved $13 million in annual revenue with over 150,000 paying customers and serves 100,000+ total users. The company experienced 10X growth in 12 months and 3000% growth in 6 months, becoming one of the top health apps on the App Store. ### What technology approach does Reframe use? Reframe uses a neuroscience-based approach that combines behavioral psychology, evidence-based methods, and habit tracking. The platform integrates scientific research to provide effective alcohol reduction tools and structured programs. ### How can I get started with Reframe? Based on the provided information, Reframe is available as a mobile app on the App Store where it ranks among the top health apps. Specific contact or signup details are not provided in the available information. ### What are the latest developments at Reframe? Reframe's most recent major development was raising $17.4 million in Series B funding in January 2022 from Goodwater Capital. The company has demonstrated exceptional growth, achieving 10X growth in 12 months and reaching over 150,000 paying customers with $13 million in annual revenue. ## Tags healthtech, saas, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*